|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,499.60 INR | -0.56% |
|
+0.13% | -1.92% |
| Dec. 12 | Ozempic launches in India at $24 a week as Novo targets booming diabetes market | RE |
| Dec. 10 | Cipla launches Yurpeak for obesity and type 2 diabetes | RE |
| Capitalization | 1,211B 13.32B 11.32B 10.59B 9.92B 18.31B 20.07B 124B 47.71B 569B 49.98B 48.94B 2,063B | P/E ratio 2026 * |
24.9x | P/E ratio 2027 * | 23.4x |
|---|---|---|---|---|---|
| Enterprise value | 1,105B 12.16B 10.33B 9.66B 9.06B 16.71B 18.32B 113B 43.54B 519B 45.61B 44.66B 1,883B | EV / Sales 2026 * |
3.78x | EV / Sales 2027 * | 3.41x |
| Free-Float |
63.97% | Yield 2026 * |
0.98% | Yield 2027 * | 1% |
Last Transcript: Cipla Limited
| 1 day | -0.56% | ||
| 1 week | +0.13% | ||
| Current month | -2.07% | ||
| 1 month | -2.12% | ||
| 3 months | -3.15% | ||
| 6 months | -0.37% | ||
| Current year | -1.92% |
| 1 week | 1,484.8 |  | 1,524.7 |
| 1 month | 1,484.8 | | 1,538.4 |
| Current year | 1,335 | | 1,673 |
| 1 year | 1,335 | | 1,673 |
| 3 years | 852 | | 1,702.05 |
| 5 years | 738.1 | | 1,702.05 |
| 10 years | 355.3 | | 1,702.05 |
| Manager | Title | Age | Since |
|---|---|---|---|
Umang Vohra
CEO | Chief Executive Officer | 53 | 2016-08-31 |
Ashish Adukia
DFI | Director of Finance/CFO | - | 2022-08-15 |
| President | - | 2019-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 89 | 1972-07-20 | |
| Director/Board Member | 72 | 2014-07-24 | |
Umang Vohra
BRD | Director/Board Member | 53 | 2016-08-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.56% | +0.13% | +3.61% | +36.10% | 13.43B | |
| -0.88% | -0.83% | -1.77% | +77.74% | 47.53B | |
| -1.23% | 0.00% | +5.65% | +100.00% | 31.61B | |
| -2.08% | -4.07% | +52.41% | - | 31.23B | |
| -0.79% | -1.11% | -6.56% | +123.78% | 10.22B | |
| -0.55% | -7.35% | +65.41% | +75.92% | 8.94B | |
| -2.28% | -4.70% | +37.99% | +105.66% | 7.06B | |
| -.--% | +0.14% | - | - | 6.79B | |
| -0.18% | +3.70% | +30.81% | -35.91% | 6.67B | |
| -0.96% | +2.32% | +29.53% | +350.57% | 6.18B | |
| Average | -0.92% | -0.17% | +24.12% | +104.23% | 16.97B | |
| Weighted average by Cap. | -1.06% | -0.23% | +18.13% | +90.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 292B 3.22B 2.73B 2.56B 2.4B 4.42B 4.85B 29.85B 11.52B 137B 12.06B 11.81B 498B | 317B 3.48B 2.96B 2.77B 2.59B 4.79B 5.25B 32.33B 12.47B 149B 13.06B 12.79B 539B |
| Net income | 48.85B 537M 456M 427M 400M 739M 809M 4.99B 1.92B 22.95B 2.02B 1.97B 83.19B | 51.95B 571M 485M 454M 426M 785M 861M 5.3B 2.05B 24.41B 2.14B 2.1B 88.47B |
| Net Debt | -106B -1.16B -989M -925M -867M -1.6B -1.75B -10.81B -4.17B -49.72B -4.37B -4.28B -180B | -132B -1.46B -1.24B -1.16B -1.08B -2B -2.19B -13.51B -5.21B -62.15B -5.46B -5.34B -225B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-16 | 1,499.60 ₹ | -0.56% | 789,492 |
| 25-12-15 | 1,508.00 ₹ | -0.62% | 855,508 |
| 25-12-12 | 1,517.40 ₹ | +0.34% | 1,054,050 |
| 25-12-11 | 1,512.30 ₹ | +1.44% | 606,130 |
| 25-12-10 | 1,490.90 ₹ | +0.02% | 1,316,274 |
Delayed Quote NSE India S.E., December 16, 2025 at 06:49 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CIPLA Stock
Select your edition
All financial news and data tailored to specific country editions
